Literature DB >> 16307418

FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up.

H Amthauer1, C Furth, T Denecke, P Hundsdoerfer, T Voelker, K Seeger, B Stöver, G Henze.   

Abstract

BACKGROUND: The use of FDG-PET was evaluated for initial staging and therapy efficacy in paediatric patients with non-Hodgkin's lymphoma (NHL) and compared to the established conventional imaging modalities (CIM). The results of this retrospective analysis are presented in conjunction with a critical review of the current literature. PATIENTS AND METHODS: Ten paediatric patients with NHL were examined using whole-body FDG-PET initially (n = 6), during therapy (n = 5) and after completion of therapy (n = 5), respectively. FDG-PET findings were compared to CIM performed according to the protocol of the German NHL-BFM 95 study. The results were evaluated for their impact on disease classification and therapy decision (St. Jude, REAL) in correspondence to a clinical follow-up of at least 24 months.
RESULTS: Concerning initial staging, all lymphoma manifestations detected by conventional imaging were also detected by FDG-PET (15 nodal, 2 extranodal). Furthermore, an additional nodal lesion was detected by FDG-PET in three patients. This resulted in an upstaging followed by an intensified poly-chemotherapy in one patient. In five patients showing unclear residual masses on conventional imaging during therapy, FDG-PET indicated viable residual tumours in one case. This patient showed a relapse during follow-up while the four FDG-PET negative patients did not. After completion of initial therapy, FDG-PET revealed in one out of five patients persistent tumour metabolism in the primary lesions and also detected new manifestations. The patient died shortly after restaging due to disease progression.
CONCLUSIONS: These first results on the use of FDG-PET in paediatric non-Hodgkin lymphoma indicate a high potential to improve the therapeutic management.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16307418     DOI: 10.1055/s-2005-872517

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  7 in total

Review 1.  FDG PET/CT in children and adolescents with lymphoma.

Authors:  Regine Kluge; Lars Kurch; Françoise Montravers; Christine Mauz-Körholz
Journal:  Pediatr Radiol       Date:  2013-03-24

2.  How PET/MR Can Add Value For Children With Cancer.

Authors:  Heike Daldrup-Link
Journal:  Curr Radiol Rep       Date:  2017-02-21

3.  The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma.

Authors:  Deepa Bhojwani; Mary B McCarville; John K Choi; Jennifer Sawyer; Monika L Metzger; Hiroto Inaba; Andrew M Davidoff; Robert Gold; Barry L Shulkin; John T Sandlund
Journal:  Br J Haematol       Date:  2014-11-10       Impact factor: 6.998

4.  Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology.

Authors:  J Stauss; C Franzius; T Pfluger; K U Juergens; L Biassoni; J Begent; R Kluge; H Amthauer; T Voelker; L Højgaard; S Barrington; S Hain; T Lynch; K Hahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

5.  Use of positron emission tomography for staging, preoperative response assessment and posttherapeutic evaluation in children with Wilms tumour.

Authors:  Daniel Misch; Ingo G Steffen; Stefan Schönberger; Thomas Voelker; Christian Furth; Brigitte Stöver; Hubertus Hautzel; Günter Henze; Holger Amthauer; Timm Denecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-29       Impact factor: 9.236

6.  Prognostic Value and Clinical Impact of (18)FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy.

Authors:  Clément Bailly; Thomas Eugène; Marie-Laure Couec; Marion Strullu; Eric Frampas; Loïc Campion; Françoise Kraeber-Bodéré; Caroline Bodet-Milin
Journal:  Front Med (Lausanne)       Date:  2014-12-16

7.  SNMMI Procedure Standard/EANM Practice Guideline on Pediatric 18F-FDG PET/CT for Oncology 1.0.

Authors:  Reza Vali; Adam Alessio; Rene Balza; Lise Borgwardt; Zvi Bar-Sever; Michael Czachowski; Nina Jehanno; Lars Kurch; Neeta Pandit-Taskar; Marguerite Parisi; Arnoldo Piccardo; Victor Seghers; Barry L Shulkin; Pietro Zucchetta; Ruth Lim
Journal:  J Nucl Med       Date:  2021-01       Impact factor: 11.082

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.